



EUROPEAN COMMISSION

Directorate-General for Environment
Circular Economy and Green Growth
Sustainable Chemicals

Directorate-General for Internal Market, Industry, Entrepreneurship and SME's
Chemicals and Consumer Industries
REACH
Chemicals and Plastic Industries

Brussels, 19/02/2021

Doc. **CA/09/2021**

38th Meeting of Competent Authorities for REACH and CLP (CARACAL)

Open session

3 – 4 March 2021

Online

- Concerns:** List of entries to be included in Annex VI of CLP (RAC opinions 2020 - preparation for 18th ATP)
- Agenda Point:** CLP-5
- Action Requested:** Competent Authorities and observers are invited to comment on the document and the discussion points put forward. Written comments should be sent by 31 March 2021 to:
GROW-CARACAL@ec.europa.eu
ENV-CARACAL@ec.europa.eu
CARACAL@echa.europa.eu

1. Background

The Annex to this document lists the substances for which RAC adopted an opinion in 2020 on the harmonised classification of certain substances. The table includes the proposed entries in Annex VI to CLP with a modified or new harmonised classification, including information on hazard class and category, hazard statements and supplementary hazard statements, applicable pictograms and signal words, as well as specific concentration limits, acute toxicity estimates (ATE) and M-factors.

For the upcoming 18th ATP to CLP, 36 new entries and 20 modified entries are recommended by RAC for inclusion in Annex VI, Part 3 of CLP.

2. Issues for discussion at CARACAL

The Commission invites Caracal members and observers to comment on the list of proposed entries for inclusion in the 18th ATP.

To facilitate the discussion and commenting at CARACAL in March 2020, the Commission would like to draw the attention to some CLH cases, for which the Commission has already received comments by concerned stakeholders, requesting re-assessment by RAC and/or non-inclusion in the 18th ATP.

These cases are:

- **2-Ethyl hexanoic acid (2-EHA)**

RAC concluded i.a. on a classification of Repr. 1B for development for 2-EHA and its salts, while the Dossier submitter has proposed to maintain the existing Repr. 2 classification. New data generated in the Substance Evaluation process under REACH (EOGRTS) was not considered sufficient by RAC to outweigh concerns about developmental effects seen in older animal studies, as well as supporting evidence on human teratogenic effects of the structurally similar substance valproic acid.

The concerned stakeholders contested the RAC opinion mainly on the grounds that

- RAC's opinion is in contradiction with the conclusions of the REACH Substance Evaluation
- RAC exceeded its mandate by modifying the classification for 2-EHA itself, not only adding classification of 2-EHA salts
- RAC disregarded new data and based classification on information for a structurally similar substance instead of using data on 2-EHA itself.

- **Ammonium bromide**

RAC concluded i.a. on a classification of Repr. 1B for fertility and development, as well as STOT RE1 for effects on the nervous system.

The concerned stakeholders contested the RAC opinion mainly on the grounds that the effects seen in animal studies are not relevant for humans, as developmental effects occur only in the presence of severe maternal effects and reprotoxic effects occur only seen at levels where severe bromism would result in humans.

- **Silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide**

RAC concluded i.a. on a classification of Acute Tox. 2; ATE (inhalation) = 0,45mg/L and STOT RE 2 (lungs)(inhalation).

The concerned stakeholders contested the RAC opinion mainly on the grounds that the classification was based on a physical effect (airway obstruction and suffocation by a large particle load) and not related to any specific toxicity of the substance.

- **Pentasodium (carboxylatomethyl)iminobis-(ethylenitrilo)tetraacetate (DTPA), Potassium 2,2',2'',2''',2''''-(ethane-1,2-diyl)nitriolo)pentacetate, N-carboxymethyl-iminobis-(ethylenitrilo)tetra(acetic acid)**

Following RAC opinion on these substances in 2017, they were included in the proposal for the 14th ATP to CLP. With regard to the RAC conclusions on Repr. 1B, the Commission requested a re-assessment by RAC following new information that had been brought forward by concerned parties during the discussion on the ATP. RAC issues an updated opinion, upholding their conclusion that the substances should be classified as Repr. 1B.

The concerned stakeholders maintain their position expressed during the discussions on the proposal for the 14th ATP that classification as Repr 1B is not justified for these substances. They contest the RAC opinion on the grounds that the reprotoxic effects in rat which are assumed to be caused by zinc sequestration in the gut, are not relevant for humans due to differences in zinc metabolism and homeostasis.

Annex

Overview of RAC opinions adopted in 2020. Presented per type of entry (i.e. new or updated).

	No. of opinions	Table
Adopted RAC opinions (2020)	56	
Proposed <u>new</u> entries to be inserted in Annex VI	36	(i)
Entries proposed <u>to be revised</u> in Annex VI	20	(ii)

(i) The following entries are inserted in accordance with the order of the entries set out in Table 3

Index No	Chemical Name	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-	Notes
				Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
014-052-00-7	silanamine, 1,1,1-trimethyl- <i>N</i> -(trimethylsilyl)-, hydrolysis products with silica; pyrogenic, synthetic amorphous, nano, surface treated silicon dioxide	272-697-1	68909-20-6	Acute Tox. 2 STOT RE 2	H330 H373 (lungs) (inhalation)	GHS06 GHS08 Dgr	H330 H373 (lungs) (inhalation)	EUH066	inhalation: ATE = 0,45 mg/L (dusts or mists)	
035-005-00-7	ammonium bromide	235-183-8	12124-97-9	Repr. 1B Lact. STOT SE 3 STOT RE 1 Eye Irrit. 2	H360FD H362 H336 H372 (nervous system) H319	GHS08 GHS07 Dgr	H360FD H362 H336 H372 (nervous system) H319			
050-032-00-4	dibutyltin bis(2-ethylhexanoate)	220-481-2	2781-10-4	Muta. 2 Repr. 1B STOT RE 1	H341 H360FD H372 (immune system)	GHS08 Dgr	H341 H360FD H372 (immune system)			
050-033-00-X	dibutyltin di(acetate)	213-928-8	1067-33-0	Muta 2 Repr. 1B STOT RE 1	H341 H360FD H372 (immune system)	GHS08 Dgr	H341 H360FD H372 (immune system)			

052-001-00-0	tellurium	236-813-4	13494-80-9	Repr. 1B Lact.	H360Df H362	GHS08 Dgr	H360Df H362			
052-002-00-6	tellurium dioxide	231-193-1	7446-07-3	Repr. 1B Lact.	H360Df H362	GHS08 Dgr	H360Df H362			
056-005-00-3	barium diboron tetraoxide	237-222-4	13701-59-2	Repr. 1B Acute Tox. 4 Acute Tox. 3	H360FD H332 H301	GHS08 GHS06 Dgr	H360FD H332 H301		inhalation: ATE = 1.5 mg/L (dusts or mists) oral: ATE = 100 mg/kg bw	
603-243-00-6	2,2-dimethylpropan-1-ol, tribromo derivative; 3-bromo-2,2-bis(bromomethyl)propan-1-ol	253-057-0	36483-57-5; 1522-92-5	Carc. 1B Muta. 2	H350 H341	GHS08 Dgr	H350 H341			
604-096-00-0	piperonyl butoxide (ISO); 2-(2-butoxyethoxy)ethyl 6-propylpiperonyl ether	200-076-7	51-03-6	STOT SE 3 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1	H335 H319 H400 H410	GHS07 GHS09 Wng	H335 H319 H410	EUH066	M=1 M=1	
604-097-00-6	2,4,6-tri-tert-butylphenol	211-989-5	732-26-3	Repr. 1B Acute Tox. 4 STOT RE 2 Skin Sens. 1B	H360D H302 H373 (liver) H317	GHS08 GHS07 Dgr	H360D H302 H373 (liver) H317		oral: ATE = 500 mg/kg bw	
604-098-00-1	4,4'-sulphonyldiphenol; bisphenol S	201-250-5	80-09-1	Repr. 1B	H360FD	GHS08 Dgr	H360FD			
606-153-00-5	benzophenone	204-337-6	119-61-9	Carc. 1B	H350	GHS08 Dgr	H350			

606-154-00-0	quinoxaline (ISO); 2-amino-3-chloro- 1,4-naphthoquinone	220-529-2	2797-51-5	Carc. 2 Repr. 2 Acute Tox. 4 STOT RE 2 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	H351 H361d H302 H373 (blood system, kidneys) H319 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H361d H302 H373 (blood system, kidneys) H319 H317 H410		oral: ATE = 500 mg/kg bw M=10 M=10	
607-756-00-6	exo-1,7,7- trimethylbicyclo[2.2. 1]hept-2-yl acrylate; isobornyl acrylate	227-561-6	5888-33-5	Skin Sens. 1A	H317	GHS07 Wng	H317			
607-758-00-7	4,4'- oxydi(benzenesulph onohydrazide)	201-286-1	80-51-3	Self-react. D Aquatic Acute 1 Aquatic Chronic 1	H242 H400 H410	GHS02 GHS09 Dgr	H242 H410		M=1 M=1	
607-757-00-1	daminozide (ISO); 4-(2,2- dimethylhydrazino)- 4-oxobutanoic acid; N- dimethylaminosucci namic acid	216-485-9	1596-84-5	Carc. 2	H351	GHS08 Wng	H351			
607-759-00-2	toluene-4- sulphonohydrazide	216-407-3	1576-35-8	Self-react. D	H242	GHS02 Dgr	H242			
607-760-00-8	2-[N-ethyl-4-[(5- nitrothiazol-2- yl)azo]-m- toluidino]ethyl acetate; C.I. Disperse Blue 124	239-203-6	15141-18-1	Skin Sens. 1A	H317	GHS07 Wng	H317		Skin Sens. 1A; H317: C ≥ 0,001%	

607-761-00-3	Perfluoroheptanoic acid; tridecafluoroheptanoic acid	206-798-9	375-85-9	Repr. 1B STOT RE 1	H360D H372 (liver)	GHS08 Dgr	H360D H372 (liver)			
607-762-00-9	methyl N-(isopropoxycarbonyl)-L-valyl-(3RS)-3-(4-chlorophenyl)-β-alaninate; valifenalate		283159-90-0	Carc. 2 Aquatic Chronic 2	H351 H411	GHS08 GHS09 Wng	H351 H411			
607-763-00-4	6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid, sodium and tris(2-hydroxyethyl)ammonium salts	-	-	Repr. 1B Eye Irrit. 2	H360FD H319	GHS08 GHS07 Dgr	H360FD H319			
607-764-00-X	6-[(C10-C13)-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid	-	2156592-54-8	Repr. 1B Eye Irrit. 2	H360FD H319	GHS08 GHS07 Dgr	H360FD H319			
607-765-00-5	6-[C12-18-alkyl-(branched, unsaturated)-2,5-dioxopyrrolidin-1-yl]hexanoic acid	-	-	Repr. 1B	H360FD	GHS08 Dgr	H360FD			
613-341-00-0	clofentezine (ISO); 3,6-bis(o-chlorophenyl)-1,2,4,5-tetrazine	277-728-2	74115-24-5	Aquatic Chronic 1	H410	GHS09 Wng	H410		M=1	

613-342-00-6	theophylline; 1,3-dimethyl-3,7-dihydro-1 <i>H</i> -purine-2,6-dione	200-385-7	58-55-9	Repr. 1B	H360D	GHS08 Dgr	H360D			
613-343-00-1	pyridalyl (ISO); 2,6-dichloro-4-(3,3-dichloroallyloxy)phenyl 3-[5-(trifluoromethyl)-2-pyridyloxy]propyl ether	-	179101-81-6	Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H317 H400 H410	GHS07 GHS09 Wng	H317 H410		M=1000 M=100	
613-344-00-7	Pyridine-2-thiol 1-oxide, sodium salt; pyriithione sodium; sodium pyriithione	223-296-5; 240-062-8	3811-73-2; 15922-78-8	Acute Tox. 3 Acute Tox. 3 Acute Tox. 4 STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 2	H331 H311 H302 H372 (nervous system) H315 H319 H317 H400 H411	GHS06 GHS08 GHS09 Dgr	H331 H311 H302 H372 (nervous system) H315 H319 H317 H410	EUH070	inhalation: ATE = 0.5 mg/L (dusts or mists) dermal: ATE = 790 mg/kg bw oral: ATE = 500 mg/kg bw M=100	
613-345-00-2	1,3,5-triazine-2,4,6-triamine; melamine	203-615-4	108-78-1	Carc. 2 STOT RE 2	H351 H373 (urinary tract)	GHS08 Wng	H351 H373 (urinary tract)			
615-046-00-2	1,3-bis(1-isocyanato-1-methylethyl)benzene; [<i>m</i> -TMXDI]	220-474-4	2778-42-9	Resp. Sens. 1 Skin Sens. 1A	H334 H317	GHS08 Dgr	H334 H317		Skin Sens. 1A; H317: C ≥ 0,001 %	
615-047-00-8	Bis(isocyanatomethyl)benzene; [<i>m</i> -XDI]	222-852-4	3634-83-1	Resp. Sens. 1 Skin Sens. 1A	H334 H317	GHS08 Dgr	H334 H317			

615-048-00-3	2,4,6-triisopropyl- <i>m</i> -phenylene diisocyanate	218-485-4	2162-73-4	Resp. Sens. 1 Skin Sens. 1	H334 H317	GHS08 Dgr	H334 H317			
616-237-00-3	fluopicolide (ISO); 2,6-dichloro- <i>N</i> -[3-chloro-5-(trifluoromethyl)-2-pyridylmethyl]benzamide	-	239110-15-7	Repr. 2	H361d	GHS08 Wng	H361d			
616-238-00-9	<i>N</i> -(2-nitrophenyl)phosphoric triamide	477-690-9	874819-71-3	Repr. 1B STOT RE 2	H360Fd H373 (kidneys)	GHS08 Dgr	H360Fd H373 (kidneys)			
616-239-00-4	<i>N</i> -(5-chloro-2-isopropylbenzyl)- <i>N</i> -cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1 <i>H</i> -pyrazole-4-carboxamide; isoflucypram	n/a	1255734-28-1	Repr. 2 Acute Tox. 4 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H361f H332 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H332 H317 H410		inhalation: ATE = 2.2 mg/L (dusts or mists) M=10 M=1	

616-240-00-X	Reaction mass of 3-(difluoromethyl)-1-methyl-N-[(1 <i>RS</i> ,4 <i>SR</i> ,9 <i>RS</i>)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide and 3-(difluoromethyl)-1-methyl-N-[(1 <i>RS</i> ,4 <i>SR</i> ,9 <i>SR</i>)-1,2,3,4-tetrahydro-9-isopropyl-1,4-methanonaphthalen-5-yl]pyrazole-4-carboxamide [$>78\%$ syn isomers $<15\%$ anti isomers relative content]; isopyrazam	-	881685-58-1	Carc. 2 Repr. 1B Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1	H351 H360D H317 H400 H410	GHS08 GHS07 GHS09 Dgr	H351 H360D H317 H410		Repr. 1B; H360D: C $\geq 3\%$ M = 10 M = 10	
650-058-00-1	Margosa, ext. [from the kernels of <i>Azadirachta indica</i> extracted with water and further processed with organic solvents]	283-644-7	84696-25-3	Repr. 2 Skin Sens. 1 Aquatic Chronic 1	H361d H317 H410	GHS08 GHS07 GHS09 Wng	H361d H317 H410		M = 10	

(ii) The entries corresponding to index numbers are replaced by the following corresponding entries:

Index No	Chemical Name	EC No	CAS No	Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)	Specific Conc. Limits, M-	Notes
014-001-00-9	trichlorosilane	233-042-5	10025-78-2	Flam. Liq. 1 Water-react. 1 Acute Tox. 3 Acute Tox. 4 Skin Corr. 1A Eye Dam. 1	H224 H260 H331 H302 H314 H318	GHS02 GHS06 GHS05 Dgr	H224 H260 H331 H302 H314	EUH014 EUH029 EUH071	inhalation: ATE = 7,6 mg/L (vapour) oral: ATE= 1000 mg/kg bw	
023-001-00-8	divanadium pentaoxide; vanadium pentoxide	215-239-8	1314-62-1	Muta. 2 Carc. 1B Repr. 2 Lact. Acute Tox. 3 Acute Tox. 2 STOT SE 3 STOT RE 1 Aquatic Chronic 2	H341 H350 H361fd H362 H301 H330 H335 H372 (respiratory tract, inhalation) H411	GHS07 GHS08 GHS09 Dgr	H341 H350 H361fd H362 H301 H330 H335 H372 (respiratory tract, inhalation) H411		inhalation: ATE = 0,05 mg/L (dusts or mists) oral: ATE = 220 mg/kg bw	
601-024-00-X	Cumene	202-704-5	98-82-8	Flam. Liq. 3 Carc. 1B Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2	H226 H350 H304 H335 H411	GHS02 GHS08 GHS07 GHS09 Dgr	H226 H350 H304 H335 H411			
601-097-00-8	Propylbenzene	203-132-9	103-65-1	Flam. Liq. 3 Asp. Tox. 1 STOT SE 3 Aquatic Chronic 2	H226 H304 H335 H411	GHS02 GHS08 GHS07 GHS09 Dgr	H226 H304 H335 H411			

603-014-00-0	2-butoxyethanol; ethylene glycol monobutyl ether	203-905-0	111-76-2	Acute Tox. 3 Acute Tox. 4 Skin Irrit. 2 Eye Irrit. 2	H331 H302 H315 H319	GHS06 Dgr	H331 H302 H315 H319		inhalation: ATE = 3 mg/L (Vapours) oral: ATE = 1200 mg/kg bw	
603-107-00-6	2-(2- methoxyethoxy)eth anol; diethylene glycol monomethyl ether	203-906-6	111-77-3	Repr. 1B	H360D	GHS08 Dgr	H360D		Repr. 1B; H360D: C ≥ 3 %	
604-030-00-0	4,4'- isopropylidenediphe nol; bisphenol A	201-245-8	80-05-7	Repr. 1B STOT SE 3 Eye Dam. 1 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H360F H335 H318 H317 H400 H410	GHS08 GHS07 GHS05 GHS09 Dgr	H360F H335 H318 H317 H410		M=1 M=10	
607-111-00-9	2-ethyl-2-[[[(1- oxoallyl)oxy]methyl]-1,3-propanediyl diacrylate; 2,2- bis(acryloyloxymeth yl)butyl acrylate; trimethylolpropane triacrylate	239-701-3	15625-89-5	Carc. 2 Skin Irrit. 2 Eye Irrit. 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1	H351 H315 H319 H317 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H315 H319 H317 H410		M=1 M=1	D

607-230-00-6	2-ethylhexanoic acid and its salts, with the exception of those specified elsewhere in this Annex			Repr. 1B	H360D	GHS08 Dgr	H360D			<p>The classification for the hazard class(es) in this entry is based only on the hazardous properties of the part of the substance which is common to all members in the entry. The hazardous properties of any member in the entry also depends on the properties of the part of the substance which is not common to all members of the group; they must be evaluated to assess whether (a) more severe classification(s) (e.g. a higher category) or (b) a broader scope of the classification (additional differentiation, target organs and/or hazard statements) might apply for the hazard class(es) in the entry.</p>
--------------	---	--	--	----------	-------	--------------	-------	--	--	--

607-253-00-1	cyfluthrin (ISO); α -cyano-4-fluoro-3-phenoxybenzyl-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane-1-carboxylate	269-855-7	68359-37-5	Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1	H362 H330 H300 H370 (nervous system) H400 H410	GHS06 GHS08 GHS09 Dgr	H362 H330 H300 H370 (nervous system) H410		inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 14 mg/kg bw M = 1000000 M = 1000000	
607-254-00-7	beta-cyfluthrin (ISO); reaction mass of rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3S)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate and rel-(R)-cyano(4-fluoro-3-phenoxyphenyl)methyl (1S,3R)-3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-1-carboxylate	-	1820573-27-0	Lact. Acute Tox. 2 Acute Tox. 2 STOT SE 1 Aquatic Acute 1 Aquatic Chronic 1	H362 H330 H300 H370 (nervous system) H400 H410	GHS06 GHS08 GHS09 Dgr	H362 H330 H300 H370 (nervous system) H410		inhalation: ATE = 0,081 mg/L (dusts or mists) oral: ATE = 11 mg/kg bw M = 1000000 M = 1000000	
607-734-00-6	pentapotassium 2,2',2'',2''',2''''-(ethane-1,2-diylnitrilo)pentaacetate	404-290-3	7216-95-7	Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2	H360D H332 H373 (inhalation) H319	GHS08 GHS07 Dgr	H360D H332 H373 (inhalation) H319		Repr. 1B; H360D: C \geq 3 % inhalation: ATE = 1,5 mg/L (dusts or mists)	
607-735-00-1	N-carboxymethylimino bis(ethylenenitrilo)tetra(acetic acid)	200-652-8	67-43-6	Repr. 1B Acute Tox. 4 STOT RE 2 Eye Irrit. 2	H360D H332 H373 (inhalation) H319	GHS08 GHS07 Dgr	H360D H332 H373 (inhalation) H319		Repr. 1B; H360D: C \geq 3 % inhalation: ATE = 1,5 mg/L (dusts or mists)	

607-736-00-7	pentasodium (carboxylatomethyl) iminobis(ethylenit rilo)tetraacetate	205-391-3	140-01-2	Repr. 1B Acute Tox. 4 STOT RE 2	H360D H332 H373 (inhalation)	GHS08 GHS07 Dgr	H360D H332 H373		Repr. 1B; H360D: C ≥ 3 % inhalation: ATE = 1,5 mg/L (dusts or mists)	
608-032-00-2	acetamiprid (ISO); (1E)-N-[(6-chloropyridin-3-yl)methyl]-N'-cyano-N-methylethanimidamide; (E)-N1-[(6-chloro-3-pyridyl)methyl]-N2-cyano-N1-methylacetamidine	-	135410-20-7 160430-64-8	Repr. 2 Acute Tox. 3 Aquatic Chronic 1 Aquatic Acute 1	H361d H301 H410 H400	GHS08 GHS06 GHS09 Dgr	H361d H301 H410		oral: ATE = 140 mg/kg bw M = 10 M = 10	
609-042-00-X	pendimethalin (ISO); N-(1-ethylpropyl)-2,6-dinitro-3,4-xylidene	254-938-2	40487-42-1	Repr. 2 Aquatic Acute 1 Aquatic Chronic 1	H361d H400 H410	GHS08 GSH09 Wng	H361d H410		M=100 M=10	
613-012-00-1	bentazone (ISO); 3-isopropyl-2,1,3-benzothiadiazine-4-one-2,2-dioxide	246-585-8	25057-89-0	Repr. 2 Acute Tox. 4 Eye Irrit. 2 Skin Sens. 1	H361d H302 H319 H317	GHS08 GHS07 Wng	H361d H302 H319 H317		oral: ATE = 1600 mg/kg bw	
615-049-00-9	1,5-naphthylene diisocyanate [containing < 0.1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	221-641-4	3173-72-6	STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3	H335 H315 H319 H334 H317 H412	GHS07 GHS08 Dgr	H335 H315 H319 H334 H317 H412			

615-050-00-4	1,5-naphthylene diisocyanate [containing ≥ 0.1 % (w/w) of particles with an aerodynamic diameter of below 50 µm]	221-641-4	3173-72-6	Acute Tox. 2 STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 Resp. Sens. 1 Skin Sens. 1A Aquatic Chronic 3	H330 H335 H315 H319 H334 H317 H412	GHS06 GHS08 Dgr	H330 H335 H315 H319 H334 H317 H412		inhalation: ATE = 0.27 mg/L (dusts or mists)	
616-164-00-7	dimoxystrobin (ISO); (2E)-2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-(methoxyimino)-N-methylacetamide; (E)-2-(methoxyimino)-N-methyl-2-[α-(2,5-xylyloxy)-o-tolyl]acetamide		149961-52-4	Carc. 2 Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1	H351 H361d H332 H400 H410	GHS08 GHS07 GHS09 Wng	H351 H361d H332 H410		inhalation: ATE = 1.3 mg/L (dusts or mists) M=100 M=100	